Grufity logoGrufity logo

Zimmer Biomet Holdings Inc Stock Research

ZBH

125.18USD-0.21(-0.17%)Market Closed

Market Summary

USD125.18-0.21
Market Closed
-0.17%

ZBH Alerts

ZBH Stock Price

ZBH RSI Chart

ZBH Valuation

Market Cap

26.3B

Price/Earnings (Trailing)

113.5

Price/Sales (Trailing)

3.78

EV/EBITDA

26.74

Price/Free Cashflow

22.48

ZBH Price/Sales (Trailing)

ZBH Profitability

EBT Margin

5.81%

Return on Equity

1.93%

Return on Assets

1.1%

Free Cashflow Yield

4.45%

ZBH Fundamentals

ZBH Revenue

Revenue (TTM)

6.9B

Revenue Y/Y

2.7%

Revenue Q/Q

9.3%

ZBH Earnings

Earnings (TTM)

231.4M

Earnings Y/Y

-55.36%

Earnings Q/Q

-167.27%

Price Action

52 Week Range

100.39134.75
(Low)(High)

Last 7 days

-0.2%

Last 30 days

1.0%

Last 90 days

-1.2%

Trailing 12 Months

4.1%

ZBH Financial Health

Current Ratio

1.88

Debt/Equity

0.44

Debt/Cashflow

0.26

ZBH Investor Care

Dividend Yield

0.77%

Dividend/Share (TTM)

0.96

Shares Dilution (1Y)

0.48%

Diluted EPS (TTM)

1.1

Peers (Alternatives to Zimmer Biomet Holdings)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
104.6B
30.8B
-8.05% -24.94%
25.73
3.4
-3.19% -17.38%
104.4B
18.4B
5.66% 8.69%
44.29
5.66
7.84% 18.25%
85.7B
6.2B
4.83% -11.02%
64.81
13.77
8.97% -22.43%
67.1B
19.0B
-1.08% -7.00%
41.67
3.53
-0.43% -8.78%
48.6B
5.4B
5.76% -25.47%
31.94
9.03
2.86% 1.25%
MID-CAP
7.2T
489.7M
12.31% 16.47%
82.2K
16.8K
106.51% 2464.23%
10.6B
847.1M
7.52% 34.43%
-5.3K
12.49
13.32% -137.89%
5.2B
1.0B
-10.91% -22.50%
30.47
5.13
6.76% 24.45%
3.6B
410.9M
10.60% -14.17%
-31.18
8.81
27.29% -14.60%
2.7B
801.2M
8.08% -61.27%
-28.75
3.39
14.00% -707.69%
SMALL-CAP
1.5B
138.6M
-22.14% 5.45%
-28.06
11.13
36.62% -10.44%
1.3B
820.0M
-2.41% -12.43%
26.08
1.61
10.13% 701.59%
942.5M
154.8M
4.20% -0.45%
-9.06
6.09
60.29% -2309.58%
828.8M
239.8M
0.30% -2.08%
-21.89
3.46
-4.74% -31.15%

Financials for Zimmer Biomet Holdings

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue0.7%6,9406,8926,9086,8896,827
  S&GA Expenses-2.8%2,7622,8402,8692,8712,843
EBITDA0.9%1,1651,1551,0501,167-
EBITDA Margin0.2%0.17*0.17*0.15*0.15*-
Earnings Before Taxes2.3%404394408386499
EBT Margin1.6%0.06*0.06*0.04*0.04*-
Interest Expenses3.6%-164-171-181-197-208
Net Income-16.7%231278230218402
Net Income Margin-17.3%0.03*0.04*0.03*0.03*-
Free Cahsflow-8.4%1,1681,2761,2941,416-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-1.3%21,06621,33321,45321,61823,456
  Current Assets-2.4%4,4274,5344,4634,5174,885
    Cash Equivalents-31.1%376545386436378
  Inventory0.9%2,1472,1292,1232,1322,148
  Net PPE3.9%1,8731,8021,7971,8261,837
  Goodwill-2.5%8,5808,7998,8698,8968,919
Liabilities-0.5%9,0399,0829,3289,59610,790
  Current Liabilities2.7%2,3582,2962,4642,6743,468
  Long Term Debt-5.3%5,2635,5605,9957,216-
    LT Debt, Current-17.4%5446598521,0151,605
    LT Debt, Non Current1.9%5,1525,0555,1725,2865,464
Shareholder's Equity-1.8%12,02012,24512,12512,02112,661
  Retained Earnings-1.9%9,5599,7409,6079,50310,292
  Additional Paid-In Capital0.4%9,5049,4649,4199,3869,315
Accumulated Depreciation0.1%4,5434,5404,4424,301-
Shares Outstanding0.1%210210209--
Minority Interest4.7%7.006.006.006.006.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-6.4%1,3561,4501,4231,4971,404
  Share Based Compensation12.8%10593.0084.0079.0076.00
Cashflow From Investing2.2%-522-533-560-416-443
Cashflow From Financing30.6%-775-1,118-1,350-1,232-1,306
  Dividend Payments0.1%201201201201200
  Buy Backs-126----

Risks for ZBH

What is the probability of a big loss on ZBH?

72.3%


Probability that Zimmer Biomet Holdings stock will be more than 20% underwater in next one year

34.6%


Probability that Zimmer Biomet Holdings stock will be more than 30% underwater in next one year.

18.5%


Probability that Zimmer Biomet Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ZBH drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Zimmer Biomet Holdings was unfortunately bought at previous high price.

Drawdowns

Returns for ZBH

Cumulative Returns on ZBH

6.7%


10-Year Cumulative Returns

3.8%


7-Year Cumulative Returns

4.3%


5-Year Cumulative Returns

17.4%


3-Year Cumulative Returns

What are the long-term rolling returns for ZBH?

FIve years rolling returns for Zimmer Biomet Holdings.

Annualized Returns

Which funds bought or sold ZBH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
added
1.29
86,573
452,573
0.01%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
657
158,479,000
177,730,000
0.19%
2023-03-08
Capital Asset Advisory Services LLC
reduced
-5.93
50,190
392,190
0.03%
2023-03-06
NORTH STAR ASSET MANAGEMENT INC
reduced
-4.8
61,297
442,297
0.03%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-31.63
-229,000
1,146,000
0.01%
2023-03-03
TIAA, FSB
added
10.48
352,585
1,368,580
-%
2023-03-02
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA
new
-
50,873
50,873
-%
2023-03-01
WHITENER CAPITAL MANAGEMENT, INC.
new
-
247,988
247,988
0.11%
2023-03-01
Lakewood Asset Management LLC
new
-
355,000
355,000
0.29%
2023-03-01
Meixler Investment Management, Ltd.
reduced
-1.45
67,980
406,980
0.41%

1–10 of 49

Latest Funds Activity

Are funds buying ZBH calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ZBH
No. of Funds

Zimmer Biomet Holdings News

MarketWatch

Zimmer Biomet Holdings Inc. stock underperforms Thursday when compared to competitors.

MarketWatch,
3 hours ago

Nasdaq

Morningstar

Investing.com India

Schedule 13G FIlings of Zimmer Biomet Holdings

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
price t rowe associates inc /md/
5.3%
11,200,109
SC 13G
Feb 09, 2023
vanguard group inc
11.46%
24,055,739
SC 13G/A
Jan 30, 2023
blackrock inc.
10.4%
21,803,709
SC 13G/A
Jan 24, 2023
blackrock inc.
10.4%
21,803,709
SC 13G/A
Apr 08, 2022
vanguard group inc
11.04%
23,102,761
SC 13G/A
Jan 28, 2022
jpmorgan chase & co
5.4%
11,340,168
SC 13G
Jan 28, 2022
blackrock inc.
10.4%
21,793,439
SC 13G/A
Apr 12, 2021
blackrock inc.
10.0%
20,926,542
SC 13G/A
Feb 11, 2021
massachusetts financial services co /ma/
4.8%
10,001,947
SC 13G/A
Feb 10, 2021
vanguard group inc
7.58%
15,703,785
SC 13G/A

ZBH Fair Value

Zimmer Biomet Holdings fair value in different scenarios

The table shows the Fair Value estimates for Zimmer Biomet Holdings for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

31.70

-74.68%

35.85

-71.36%

41.30

-67.01%

54.91

-56.14%

64.23

-48.69%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Zimmer Biomet Holdings Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Zimmer Biomet Holdings

View All Filings
Date Filed Form Type Document
Mar 21, 2023
4
Insider Trading
Mar 17, 2023
144
Notice of Insider Sale Intent
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading

Latest Insider Trading transactions for ZBH

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-17
Phipps Chad F
sold
-2,869,110
124
-23,045
sr. vp/gen counsel/secretary
2023-03-17
Phipps Chad F
acquired
1,635,500
70.97
23,045
sr. vp/gen counsel/secretary
2023-03-02
Winkler Lori
sold (taxes)
-6,839
122
-56.00
svp and chro
2023-03-02
Winkler Lori
acquired
-
-
187
svp and chro
2023-02-21
Tornos Ivan
sold (taxes)
-203,060
124
-1,628
chief operating officer
2023-02-21
Hanson Bryan C
acquired
-
-
15,132
president and ceo
2023-02-21
Hanson Bryan C
sold (taxes)
-592,717
124
-4,752
president and ceo
2023-02-21
Upadhyay Suketu
acquired
-
-
3,860
exec. vp, cfo
2023-02-21
Ellingson Rachel
acquired
-
-
1,046
svp & chief strategy officer
2023-02-21
Yi Sang
acquired
-
-
2,423
president, asia pacific

1–10 of 50

Bryan C. Hanson
19500
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

ZBH Income Statement

2022-12-31
Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Net Sales$ 6,939.9$ 6,827.3$ 6,127.5
Type of Revenue [Extensible List]us-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMember
Cost of products sold, excluding intangible asset amortization$ 2,019.5$ 1,960.4$ 1,824.3
Type of Cost, Good or Service [Extensible List]us-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMember
Intangible asset amortization$ 526.8$ 529.5$ 512.1
Research and development406.0435.8322.8
Selling, general and administrative2,761.72,843.42,712.7
Goodwill and intangible asset impairment292.816.3503.0
Restructuring and other cost reduction initiatives191.6125.7107.2
Quality remediation33.852.850.9
Acquisition, integration, divestiture and related11.43.111.4
Operating expenses6,243.65,967.06,044.4
Operating Profit696.3860.383.1
Other (expense) income, net(128.0)12.223.8
Interest expense, net(164.8)(208.4)(212.1)
Loss on early extinguishment of debt (165.1) 
Earnings (Loss) before income taxes403.5499.0(105.2)
Provision (benefit) for income taxes from continuing operations112.353.5(96.0)
Net Earnings (Loss) from Continuing Operations291.2445.5(9.2)
Less: Net earnings attributable to noncontrolling interest1.00.51.5
Net Earnings (Loss) from Continuing Operations of Zimmer Biomet Holdings, Inc.290.2445.0(10.7)
Loss from Discontinued Operations, Net of Tax(58.8)(43.4)(128.2)
Net Earnings (Loss) of Zimmer Biomet Holdings, Inc.$ 231.4$ 401.6$ (138.9)
Basic Earnings (Loss) Per Common Share   
Earnings (Loss) from Continuing Operations$ 1.38$ 2.14$ (0.05)
Loss from Discontinued Operations(0.28)(0.21)(0.62)
Basic Earnings (Loss) Per Common Share1.101.93(0.67)
Diluted Earnings (Loss) Per Common Share   
Earnings (Loss) from Continuing Operations1.382.12(0.05)
Loss from Discontinued Operations(0.28)(0.21)(0.62)
Diluted Earnings (Loss) Per Common Share$ 1.10$ 1.91$ (0.67)
Weighted Average Common Shares Outstanding   
Basic209.6208.6207.0
Diluted210.3210.4207.0

ZBH Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Current Assets:  
Cash and cash equivalents$ 375.7$ 378.1
Accounts receivable, less allowance for credit losses1,381.51,259.6
Inventories2,147.22,148.0
Prepaid taxes198.4326.7
Prepaid expenses and other current assets324.5271.0
Current assets of discontinued operations 501.6
Total Current Assets4,427.34,885.0
Property, plant and equipment, net1,872.51,836.6
Goodwill8,580.28,919.4
Intangible assets, net5,063.85,533.6
Other assets1,122.21,005.0
Noncurrent assets of discontinued operations 1,276.8
Total Assets21,066.023,456.4
Current Liabilities:  
Accounts payable354.1306.5
Income taxes payable38.562.0
Other current liabilities1,421.31,317.1
Current portion of long-term debt544.31,605.1
Current liabilities of discontinued operations 177.2
Total Current Liabilities2,358.23,467.9
Deferred income taxes, net474.8558.5
Long-term income tax payable421.2583.0
Other long-term liabilities632.6548.5
Long-term debt5,152.25,463.7
Noncurrent liabilities of discontinued operations 168.4
Total Liabilities9,039.010,790.0
Commitments and Contingencies (Note 21)
Stockholders' Equity:  
Common stock, $0.01 par value, one billion shares authorized,313.8 million (312.8 million in 2021) issued3.13.1
Paid-in capital9,504.49,314.8
Retained earnings9,559.310,292.2
Accumulated other comprehensive loss(179.3)(231.6)
Treasury stock, 104.8 million shares (103.8 million shares in 2021)(6,867.2)(6,717.8)
Total Zimmer Biomet Holdings, Inc. stockholders' equity12,020.312,660.7
Noncontrolling interest6.75.7
Total Stockholders' Equity12,027.012,666.4
Total Liabilities and Stockholders' Equity$ 21,066.0$ 23,456.4